Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 30

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 30
---
 Inc.                |     | Gritstone bio, Inc.          |     | Sana Biotechnology, Inc.    |
| BioAtla, Inc.                   |     | Harpoon Therapeutics, Inc.   |     | Terns Pharmaceuticals, Inc. |
|                                 |     |                              |     | Vor Biopharma Inc.          |

The peer group was recommended by Anderson and consisted of companies operating in the biopharmaceutical/biotechnology industry and generally had fewer than 150 employees, market capitalization between $150 million and $750 million, and a lead development program in Phase 2. The stage of clinical development of ourselves and many of our peers renders us and them pre-commercial, and so revenues were not a meaningful factor considered in selecting our peer group. Some companies in the peer group were outside of one or more of these parameters but were included because their business areas of focus were similar to ours. Summary Compensation Table The table below sets forth the compensation earned or paid to our executive officers identified below, who under SEC rules are considered our named executive officers, for 2024. Under SEC rules, the following individuals are considered a company’s named executive officers: (1) all individuals serving as the company’s principal executive officer or acting in a similar capacity during the last completed fiscal year, regardless of compensation level, which for us was Mr. Culley; (2) the company’s two most highly compensated executive officers other than its principal executive officer who were serving as executive officers at the end of the last completed fiscal year, which for us were Ms. Howe and Mr. Samuel; and (3) up to two additional individuals for whom disclosure would have been provided pursuant to the preceding clause (2) but for the fact that the individual was not serving as an executive officer of the company at the end of the last completed fiscal year. There was no individual who fit the description in clause (3) of the preceding sentence for 2024.

| 2024 Summary Compensation Table         
 Name and Principal Position             |     | Fiscal 
   Year |     | Salary 
 ($)    |         |     | Option 
 Awards 
 ($)(1) |           |     | Non-Equity Incentive Plan Compensation ($)(2) |         |     | All Other    
 Compensation 
 ($)(3)       |        |     | Total 
 ($)   |           |
|:----------------------------------------|:----|-------:|:----|:-------|--------:|:----|:-------|----------